Positive high-level results from the ADAURA phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2 and 3a) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Positive high-level results from a planned interim analysis of the AEGEAN phase III, placebo-controlled trial showed that treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage (2a-3b) non-small cell lung cancer.
New insights into the effects of a hormonal treatment for transgender men, discovered by Cedars-Sinai investigators, could have implications for the treatment of breast cancer.
Researchers at NCI Center for Cancer Research have identified extrachromosomal DNA as a major driver of small cell lung cancer, highlighting a novel biomarker and therapeutic target that could be used to eliminate the most aggressive and shapeshifting SCLC cells. The study was published in Cancer Discovery.
Given the lack of research into oncology-related telehealth, researchers at Trilliant Health sought to better understand the scope of oncology-related telehealth and the demographics of those patients, relative to telehealth patients writ large.
Cell membrane protrusions called blebs that typically signify the end of life for healthy cells do the opposite for melanoma cells, activating processes in these cells that help them to survive and spread, a UT Southwestern study suggests.
How estrogen receptor-positive breast cancer responds to hormone therapy may hold keys to understanding how it will respond to radiation therapy, and an experimental drug that increases the effectiveness of hormone therapy also overcomes radiation resistance in breast cancer, a study by UT Southwestern Medical Center researchers shows.
Research from the University of Wisconsin indicates that for patients with breast cancer, the cancer’s stage and receptor status can help clinicians predict whether and when cancer might recur after initial treatment.
Despite racial and ethnic minority groups making up nearly half of the United States population, underrepresentation in clinical trials remains a critical challenge. In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine partnered with The African American Male Wellness Agency, Genentech Inc., and Pfizer, Inc. to engage with almost 450 community members in 25 states and five countries to create solutions to barriers of access, awareness, discrimination and racism, and workforce diversity.
A study found that recent increases in Medicare spending on outpatient cancer care at the end of patients’ lives were driven almost entirely by a type of treatment given to fewer than 1 in 5 patients.
